News about Merus N V

Merus Doses First Patient in Phase 3 Trials for Petosemtamab in Oncology Indications
Sep 30 2024
Merus N.V., a clinical-stage oncology company specializing in the development of innovative multispecific antibodies, has announced significant advanc...

Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
Aug 01 2024
Leveraging Combination Therapy: Promising Interim Results for Petosemtamab and Pembrolizumab in Oncology*Abstract*In the rapidly evolving landscape o...

Merus Advances Oncology Frontiers Phase 3 Trials for Petosemtamab and Promising Data for MCLA-129 Highligh...
Jul 24 2024
*UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 3, 2024* ?? Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company specializing in multispe...

Merus Doses First Patient in Phase 2 Trial of Petosemtamab for mCRC and Announces Advancements in Oncology Trea...
Jul 08 2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 ?? Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company specializing in the devel...

Merus N.V.s MCLA-129 Shines in METex14 NSCLC: Significant Clinical Promise Coincides with Revenue Surge ...
Jun 03 2024
---*Abstract*Merus N.V., a clinical-stage oncology company specializing in multispecific antibodies, showcased promising single-agent efficacy results...

Merus N.V. Raises $400.2 Million in Upsized Public Offering, Fuelling Innovation in Oncology
May 30 2024
Merus N.V. Announces Pricing of Upsized Public Offering of Common Shares, Raises Approximately $400.2 MillionMerus N.V., a clinical-stage oncolog...

Merus N.V. Pursues $300 Million Public Offering to Fuel Innovative Cancer Treatment Development
May 28 2024
Merus N.V. Seeks $300 Million Through Proposed Public Offering of Common SharesUTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 - Mer...

Sobi Receives Fast Track Designation for Revolutionary Macrophage Activation Syndrome Therapy, While Merus N V Reports Impressive Revenue Growth in the Biopharmaceutical Sector
May 24 2024
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg Being Investigated in Macrophage Activation SyndromeIn an exciting development for the...

Merus N.V. Unveils Pivotal Oncology Innovations at ASCO, AACR, and ESMO 2024: MCLA-145, Zeno, and MCLA-129 Take Center Stage in Cancer Research
May 23 2024
UTRECHT, The Netherlands, and CAMBRIDGE, Mass., April 08, 2024 ?? Merus N.V. (Nasdaq: MRUS), a clinical-stage company known for its innovative approac...

Groundbreaking Biotech Advancements: Cyprus Authorizes Vestaron*s Bioinsecticide and Merus*s Novel Cancer Therapy Undergoes FDA Review
May 14 2024
Cyprus has joined the ranks of European countries endorsing the use of bioinsecticides, issuing emergency use authorization for Vestaron*s SPEAR LEP b...

Merus N V Experiences Impressive Revenue Surge and Substantial Reduction in Losses, Signaling Strong Growth in the Major Pharmaceutical Preparations Industry
Nov 03 2023
Respectable Revenue Rise for Merus N V in Q3 2023: A Promising Outlook for the Major Pharmaceutical Preparations IndustryIn its recently released...

Loss larger than a year ago at the Merus N V in the April to June 30 2023 fiscal period
Aug 08 2023
Merus N.V, a prominent pharmaceutical company, recently released its financial results for the fiscal period of April to June 2023. These re...

Major Pharmaceutical Preparations Company, Merus N V, Witnesses Widened Losses as First Quarter 2023 Earnings Season Unfolds
May 05 2023
As an investor, it is important to exercise caution when considering a stock with a cumulative net loss of $-152 million in the 12 months ending in th...